Leading R&D and product development projectsTravel to see customersGiving presentations nad posters to engelize CDI's product offerings at conferecens and other industry meetingsApplications supportAdvanced research on CDI's technologies working closely with the CSO and COO

Pioneering Research: Led groundbreaking studies to identify and characterize potential ligands for the orphan GPCR GPRC5B, revealing its critical role in adipocyte signaling and inflammation. These discoveries not only advanced our understanding of type II diabetes mechanisms but also established GPRC5B as a promising therapeutic target with the potential to transform diabetes treatment strategies.Innovative Screening Methodologies: Developed a cutting-edge screening approach using Virion Display protein microarray technology for Transient Receptor Potential (TRP) channels. This novel methodology accelerated drug discovery efforts, facilitating the identification of a new class of highly effective analgesics for pain management.Combinatorial Screening Techniques: Created an advanced combinatorial screening method by integrating Virion Display technology with one-bead-one-compound combinatorial peptide synthesis. This innovative approach enabled multiplexed screening for new peptide modulators targeting GPCRs, providing significant insights into potential therapeutic interventions for various diseases.Next-Generation Biologics: Utilized Virion Display to perform comprehensive screenings of antibody, RNA aptamer, peptide, and small molecule libraries. This transformative strategy aimed to identify next-generation biologics for disease treatment, holding immense promise for developing advanced therapeutic modalities to address unmet medical needs and redefine standards of care.Mentorship and Training: Mentored and trained a dynamic team of one undergraduate and three rotation students in cutting-edge techniques, fostering a culture of excellence and innovation in scientific inquiry.

• Collaborate directly with CDI Laboratories CEO to spearhead the development of a product launch strategy for Virion Display microarray technology.• Leading efforts to expand the Virion Display library to encompass all transmembrane proteins, pioneering the creation of a groundbreaking protein microarray library capable of simultaneously assaying all transmembrane proteins—a first-of-its-kind innovation in the field that facilitates positive and negative screening for any molecule.• Experience includes assay development and optimization, forecasting of expenses, delivering compelling pitches to investors, and crafting detailed product launch timelines

Research assistant in Cerione Lab in the Department of Molecular medicine at Cornell University. Study protein signaling and changes in protein cargo in extracellular vesicles following oncogenic transformation.

Assisted in a project that was studying the interaction between KRas and the receptor GPR31 to see if this would be a way to inhibit Ras association with the plasma membrane and prohibit it's function.